Group 1 - The core viewpoint of the article highlights the company's strategy to enhance the value of the Wanglaoji brand by expanding its distribution network and collaborating with major restaurant platforms [1] - The company is focusing on promoting bottled beverages and exploring new product lines, including original flavor herbal tea and various fruit-flavored juice products, to cultivate a second growth curve [1] - In the functional beverage segment, the company has launched Wanglaoji Flash Recharge Electrolyte Water, indicating its commitment to innovation in product offerings [1]

Core Viewpoint - The company announced its participation in the national organized procurement for the continuation of products from the first to eighth batches, aiming to secure contracts for 24 pharmaceutical products, including injectable Cefuroxime Sodium and Clindamycin Phosphate Injection [1] Group 1: Company Participation - The company’s subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., and its branch, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., are involved in the procurement process [1] - The products targeted for procurement include Cefuroxime Sodium Injection, Clindamycin Phosphate Injection, Mebendazole Tablets, and Amoxicillin Granules among others [1] Group 2: Procurement Details - The procurement is based on the demand reported by medical institutions for each enterprise's products, with the selection price gradient determining the volume ratio [1] - The procurement cycle will last from the actual execution date of the selection results until December 31, 2028 [1]

Core Viewpoint - The company announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its injectable penicillin sodium, indicating successful compliance with the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The injectable penicillin sodium is approved in a dosage of 0.96g (1.6 million units) [1] - This medication is indicated for various infections caused by sensitive bacteria, including abscesses, bacteremia, pneumonia, and endocarditis [1]

Group 1 - The company, Baiyunshan, announced that its subsidiaries, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., participated in the national centralized procurement for the continuation of products whose agreements have expired [1] - A total of 24 products, including Cefuroxime Sodium Injection and Clindamycin Phosphate Injection, are proposed to be selected for this procurement, which is based on the demand reported by medical institutions [1] - The procurement cycle will last until December 31, 2028, starting from the actual execution date of the selected results [1] Group 2 - The total projected sales revenue for the selected products in 2024 is approximately RMB 798 million, accounting for 1.06% of the company's total revenue for that year [2] - For the first three quarters of 2025, the projected sales revenue is about RMB 550 million, representing 0.89% of the company's revenue during that period [2] - If contracts are signed and implemented, it will further increase product sales, enhance market share, and positively impact the company's brand image and future business development [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 關於部分藥品在國家組織集采藥品協議期滿品種接續採購中擬中選的公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 证券代码：600332 证券简称：白云山 公告编号：2026-008 广州白云山医药集团股份有限公司 关于部分药品在国家组织集采药品协议期满品种 接续采购中拟中选的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（以下简称"公司"）控股子 公司广州白云山天心制药股份有限公司（以下简称"天心制药"）及 分公司广州白云山医药集团股份有限公司白云山制药总厂（以下简称 "白 ...

Core Viewpoint - The company Baiyunshan (600332.SH) announced that its subsidiary Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for its injectable penicillin sodium (0.96g, 1.6 million units), which has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The injectable penicillin sodium is indicated for various infections caused by sensitive bacteria, including abscesses, bacteremia, pneumonia, and endocarditis [1] - Penicillin is the preferred drug for infections such as hemolytic streptococcal infections, pneumococcal infections, and infections caused by penicillinase-negative staphylococci [1] - The drug is also effective against anthrax, tetanus, gas gangrene, syphilis (including congenital syphilis), leptospirosis, relapsing fever, diphtheria, and in combination with aminoglycosides for treating viridans streptococcal endocarditis [1]

Core Viewpoint - The announcement highlights that Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.'s subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., has received approval for its injectable penicillin sodium product, which is expected to enhance its market competitiveness [1] Group 1 - The product, injectable penicillin sodium 0.96g (1.6 million units), has passed the consistency evaluation for generic drug quality and efficacy [1] - The research and development expenses incurred by Tianxin Pharmaceutical for this product amount to approximately RMB 2.5926 million (unaudited) [1] - The approval is seen as a positive development for the company's product portfolio, potentially increasing its market share [1]

Core Viewpoint - The company Baiyunshan (00874) announced that its subsidiary Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for its injectable penicillin sodium 0.96g (1.6 million units), which has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The injectable penicillin sodium is indicated for various infections caused by sensitive bacteria, including abscesses, bacteremia, pneumonia, and endocarditis [1] - Penicillin is the first-line drug for infections such as hemolytic streptococcal infections, pneumococcal infections, and infections caused by penicillinase-negative staphylococci [1] - The drug is also effective against anthrax, tetanus, gas gangrene, syphilis (including congenital syphilis), leptospirosis, relapsing fever, diphtheria, and in combination with aminoglycosides for treating viridans streptococcal endocarditis [1]

证券代码：600332 证券简称：白云山 公告编号：2026-008 广州白云山医药集团股份有限公司 关于部分药品在国家组织集采药品协议期满品种 接续采购中拟中选的公告 2 | | | | 染;(8)中枢神经系统感染。 适用于治疗敏感微生物引起的单 | | --- | --- | --- | --- | | | | 0.5g | 一或多重感染：(1)全身性重度感 染；(2)下呼吸道感染(包括肺炎)； | | | | | (3)耳鼻喉感染；(4)尿路感染；(5) | | | | | 皮肤和软组织感染；(6)骨和关节 | | | 注射用头孢他啶 | | 感染；(7)妇科感染；(8)胃肠道、 | | | | | 胆道和腹部感染；(9)血液/腹膜透 | | | | | 析 和 持 续 性 非 卧 床 腹 膜 透 析 | | | | 1.0g | (CAPD)相关感染；(10)中枢神经系 | | | | | 统感染(包括脑膜炎)；(11)预防围 | | | | | 手术期尿路感染。 | | | | | 适用于治疗敏感细菌所致的中耳 | | | | 0.5g | 炎、支气管炎、肺炎等呼吸道感染、 | | | | | 尿路 ...

证券代码：600332 证券简称：白云山 公告编号：2026-007 一、药品的基本情况 药品通用名称：注射用青霉素钠 通知书编号：2026B00785 受理号：CYHB2450644 剂型：注射剂 规格：0.96g（160万单位）（按C16H17N2NaO4S计） 注册分类：化学药品 广州白云山医药集团股份有限公司 关于子公司药品通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 控股子公司广州白云山天心制药股份有限公司（以下简称"天心制药"） 收到国家药品监督管理局核准签发的《药品补充申请批准通知书》， 注射用青霉素钠0.96g（160万单位）已通过仿制药质量和疗效一致性 评价。现将有关情况公告如下： 二、药品的相关信息 天心制药注射用青霉素钠0.96g（160万单位）于1991年上市。天 心制药于2024年12月16日向国家药品监督管理局递交注射用青霉素 钠0.96g（160万单位）一致性评价申请，于2024年12月31日获得受理。 药品 ...